Articles by Josh Roberts

Foot soldiers in the "Omics revolution" have an ally in the BioOdyssey Calligrapher MiniArrayer, a new entry into the benchtop microarray printing arena from Bio-Rad Laboratories.

and many since have sought to explain correlations between a gene's physical location and its activity.

With just a few protein comprising 85% to 90% of human serum, low-abundance components can be difficult to identify by mass spectrometry.

Researchers often use immunoprecipitation (IP) to isolate specific proteins from complex samples or to identify protein-protein interactions.

Bert Vogelstein has an unusual complaint about the humans whose genetic defects he studies: "We're diploid."

Integrated viral sequences can dysregulate genes.

The massive efforts to systematically find and catalog single nucleotide polymorphisms (SNPs) bear witness to the conviction that small genomic changes may provide clues to the origins of such things as heart problems, obesity, and pharmacologic responses.

The immune system is often likened to the military.

has hardly put an end to mapping studies.

Sometimes, the number of times a paper has been cited barely begins to describe the importance of the work.

Courtesy of Georgia Institute of TechnologyMost patients with insulin-dependent diabetes still control their blood glucose levels with a poke in the finger and a shot in the arm. While that crude but effective procedure is years away from being replaced on a large scale, many are looking to deliver insulin and other drugs in a more foolproof, less invasive manner.Associate professor Andrew Lyon's lab at the Georgia Institute of Technology has developed a thin, self-assembling, layered hydrogel f

© Christopher Zacharow/Images.comGene therapy's heady days of introducing the gene for adenosine deaminase into immune cells to treat a life-threatening congenital defect, as was done in the first gene therapy trial in 1990, have given way to an atmosphere of caution. In 1999, Jesse Gelsinger died of multiple organ failure four days after receiving adenovirus-based therapy for a rare liver disorder. In 2002, a child developed leukemia after receiving retroviral therapy for X-linked severe c

Aaron Klug's career has taken many turns, spanning physics, biology, chemistry, and administration. 

An effective HIV vaccine has yet to be created, and maybe one never will. Scientists working on protective vaccines have mountains of problems with the virus' slippery nature, but perhaps most unnerving is that a vaccine-primed immune system might be more susceptible to infection. Boosting the HIV-specific helper cells may be giving the virus more factories in which to reproduce.T helper (Th) cells have a "dual role as target cells for infection, as well as being important mediators of the host

Six years ago, when John Tinsley's postdoctoral advisor at Texas A&Mtold him to find a protocol to introduce proteins into coronary endothelial cells, he couldn't find one in the literature. Tinsley tested a variety of commercial DNA transfection reagents, found one that worked for proteins, and has been using it since then.Tinsley's experience would be a lot different today. No longer must researchers rely on tedious and toxic procedures, or on proprietary reagents designed specifically for